Comprehension of drug toxicity: Software and databases

Computers in Biology and Medicine

Volumn 45, Issue 1, 2014, Pages 20-25

  Toropov, Andrey A ^a   Toropova, Alla P ^a   Raska, Ivan ^b   Leszczynska, Danuta ^c   Leszczynski, Jerzy ^d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Jackson State University   (United States)

^d JACKSON STATE UNIVERSITY   (United States)

Author keywords

Computational toxicology; Drug toxicity; In silico methods; In silico toxicology; QSAR

Indexed keywords

COMPUTATIONAL MODEL; COMPUTATIONAL TOXICOLOGY; DYNAMIC EVOLUTION; IN-SILICO; QSAR; QUANTITATIVE STRUCTURE-PROPERTY/ACTIVITY RELATIONSHIPS; ROBUST PREDICTIONS; TOXICITY PREDICTIONS;

BIOLOGY; COMPUTATIONAL CHEMISTRY; FORECASTING;

TOXICITY;

ARTICLE; BIOLOGY; CARCINOGENICITY; CARDIOTOXICITY; CHEMISTRY; COMPREHENSION; COMPUTER MODEL; COMPUTER PROGRAM; COST; DRUG DATABASE; DRUG DEVELOPMENT; DRUG TOXICITY; EVALUATION; MONTE CARLO METHOD; MUTAGENICITY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION; TIME;

COMPUTATIONAL TOXICOLOGY; DRUG TOXICITY; IN SILICO METHODS; IN SILICO TOXICOLOGY; QSAR;

ANIMALS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE; TOXICITY TESTS;

EID: 84890016373     PISSN: 00104825     EISSN: 18790534     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2013.11.013     Document Type: Article

References (44)

1. Valerio L.G. Predictive computational toxicology to support drug safety assessment. Methods Mol. Biol. 2013, 930:341.
2. Makhaeva G.F., Radchenko E.V., Palyulin V.A., Rudakova E.V., Aksinenko A.Y., Sokolov V.B., Zefirov N.S., Richardson R.J. Organophosphorus compound esterase profiles as predictors of therapeutic and toxic effects. Chem. Biol. Interact. 2013, 203:231.
3. Speck-Planche A., Kleandrova V.V., Cordeiro M.N.D.S. New insights toward the discovery of antibacterial agents: multi-tasking QSBER model for the simultaneous prediction of anti-tuberculosis activity and toxicological profiles of drugs. Eur. J. Pharm. Sci. 2013, 48:812.
4. Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol. Inf. 2010, 29:476.
5. Yadav D.K., Khan F., Negi A.S. Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity. J. Mol. Model. 2012, 18:2513.
6. Yadav D.K., Khan F. QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase-I. J. Chemom. 2013, 27:21.
7. Perisic-Janjic N., Kaliszan R., Milosevic N., Uscumlic G., Banjac N N. Chromatographic retention parameters in correlation analysis with in silico biological descriptors of a novel series of N-phenyl-3-methyl succinimide derivatives. J. Pharm. Biomed. Anal. 2013, 72:65.
8. Segan S., Trifkovic J., Verbic T., Opsenic D., Zlatovic M., Burnett J., Solaja B., Milojkovic-Opsenic D. Correlation between structure, retention, property, and activity of biologically relevant 1,7-bis(aminoalkyl)diazachrysene derivatives. J. Pharm. Biomed. Anal. 2013, 72:231.
9. Fourches D., Barnes J.C., Day N.C., Bradley P., Reed J.Z., Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem. Res. Toxicol. 2010, 23:171.
10. Frid A.A., Matthews E.J. Regul. Toxicol. Pharm. 2010, 56:276. Prediction of drug-related cardiac adverse effects in humans-B: use of QSAR programs for early detection of drug-induced cardiac toxicities.
11. Roy K., Mitra I. Electrotopological state atom (E-State) index in drug design, QSAR, property prediction and toxicity assessment. Curr. Comput. Aided Drug Des. 2012, 8:135.
12. Kortagere S., Ekins S. Troubleshooting computational methods in drug discovery. J. Pharmacol. Toxicol. Methods 2010, 61:67.
13. Fernandez M., Caballero J., Fernandez L., Sarai A. Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM). Mol. Diversity 2011, 15:269.
14. Kar S., Roy K. Development and validation of a robust model for prediction of carcinogenicity of drugs. Indian J. Biochem. Biophys. 2011, 48:111.
15. Valerio L.G., Cross K.P. Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities. Toxicol. Appl. Pharm. 2012, 260:209.
16. Ruark C.D., Hack C.E., Robinson P.J., Paul E., Anderson P.E., Gearhart J.M. Quantitative structure-activity relationships for organophosphates binding to acetylcholinesterase. Arch. Toxicol. 2013, 87:281.
17. Bartels M., Ricka D., Lowe E., Loizou G., Price P., Spendiff M., Arnold S., Cocker J., Ball N. Development of PK- and PBPK-based modeling tools for derivation of biomonitoring guidance values. Comput. Meth. Prog. Biol. 2012, 108:773.
18. Chen A., Yarmush M.L., Maguire T. Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues. Curr. Drug Metab. 2012, 13:863.
19. Kirchmair J., Williamson M.J., Tyzack J.D., Tan L., Bond P.J., Bender A., Glen R.C. Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms. J. Chem. Inf. Model. 2012, 52:617.
20. Toropov A.A., Toropova A.P., Raska I., Benfenati E., Gini G. QSAR modeling of endpoints for peptides which is based on representation of the molecular structure by a sequence of amino acids. Struct. Chem. 2012, 23:1891.
21. Toropova A.P., Toropov A.A., Rasulev B.F., Benfenati E., Gini G., Leszczynska D., Leszczynski J. QSAR models for ACE-inhibitor activity of tri-peptides based on representation of the molecular structure by graph of atomic orbitals and SMILES. Struct. Chem. 2012, 23:1873.
22. Toropov A.A., Toropova A.P., Raska I., Benfenati E., Gini G. Development of QSAR models for predicting anti-HIV-1 activity using the Monte Carlo method. Cent. Eur. J. Chem. 2013, 11:371.
23. Toropova A.P., Toropov A.A., Benfenati E., Leszczynska D., Leszczynski J. QSAR modeling of measured binding affinity for fullerene-based HIV-1 PR inhibitors by CORAL. J. Math. Chem. 2010, 48:959.
24. Toropov A.A., Toropova A.P., Benfenati E., Leszczynska D., Leszczynski J. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance. Eur. J. Med. Chem. 2010, 45:1387.
25. Toropov A.A., Toropova A.P., Benfenati E., Leszczynska D., Leszczynski J. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations. J. Comput. Chem. 2010, 31:381.
26. Toropov A.A., Toropova A.P., Benfenati E., Gini G., Puzyn T., Leszczynska D., Leszczynski J. Novel application of the CORAL software to model cytotoxicity of metal oxide nanoparticles to bacteria Escherichia coli. Chemosphere 2012, 89:1098.
27. Puzyn T., Rasulev B., Gajewicz A., Hu X., Dasari T.P., Michalkova A., Hwang H.-M., Toropov A., Leszczynska D., Leszczynski J. Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles. Nat. Nanotechnol. 2011, 6:175.
28. Gajewicz A., Rasulev B., Dinadayalane T.C., Urbaszek P., Puzyn T., Leszczynska D., Leszczynski J. Advancing risk assessment of engineered nanomaterials: application of computational approaches. Adv. Drug Delivery Rev. 2012, 64:1663.
29. Hamon V., Horvath D., Gaudin C., Desrivot J., Junges C., Arrault A., Bertrand M., Vayer P. QSAR modelling of CYP3A4 inhibition as a screening tool in the context of drug-drug interaction studies. Mol. Inf. 2012, 31:669.
30. Ishikawa T., Hirano H., Saito H., Sano K., Ikegami Y., Yamaotsu N., Hirono S. Quantitative structure-activity relationship (QSAR) analysis to predict drug-drug interactions of ABC transporter ABCG2. Mini-Rev. Med. Chem. 2012, 12:505.
31. Rhoades J.A., Peterson Y.K., Zhu H.J., Appel D.I., Peloquin C.A., Markowitz J.S. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. Pharm. Res. 2012, 29:972.
32. Mullard A. FDA drug approvals. Nat. Rev. Drug Discovery 2010, 10(2011):82.
33. Helguera A.M., Combes R.D., Pérez González M., Cordeiro M.N.D.S. Applications of 2D descriptors in drug design: a DRAGON tale. Curr. Top. Med. Chem. 2008, 8:1628.
34. Dobo K.L., Greene N., Fred C., Glowienke S., Harvey J.S., Hasselgren C., Jolly R., Kenyon M.O., Munzner J.B., Muster W., Neft R., Reddy M.V., White A.T., Weiner S. In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry survey. Regul. Toxicol. Pharm. 2012, 62:449.
35. Valerio L.G. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol. 2009, 241:356.
36. Kar S., Roy K. Predictive toxicology using QSAR: a perspective. J. Indian Chem. Soc. 2010, 87:1455.
37. Myshkin E., Brennan R., Khasanova T., Sitnik T., Serebriyskaya T., Litvinova E., Guryanov A., Nikolsky Y., Nikolskaya T., Bureeva S. Prediction of organ toxicity endpoints by QSAR modeling based on precise chemical-histopathology annotations. Chem. Biol. Drug Des. 2012, 80:406.
38. Ibezim E., Duchowicz P.R., Ortiz E.V., Castro E.A. QSAR on aryl-piperazine derivatives with activity on malaria. Chemom. Intell. Lab. Syst. 2012, 110:81.
39. Garro Martinez J.C., Duchowicz P.R., Estrada M.R., Zamarbide G.N., Castro E.A. QSAR study and molecular design of open-chain enaminones as anticonvulsant agents. Int. J. Mol. Sci. 2011, 12:9354.
40. García J., Duchowicz P.R., Rozas M.F., Caram J.A., Mirífico M.V., Fernández F.M., Castro E.A. A comparative QSAR on 1,2,5-thiadiazolidin-3-one 1,1-dioxide compounds as selective inhibitors of human serine proteinases. J. Mol. Graphics Modell. 2011, 31:10.
41. Mullen L.M.A., Duchowicz P.R., Castro E.A. QSAR treatment on a new class of triphenylmethyl-containing compounds as potent anticancer agents. Chemom. Intell. Lab. Syst. 2011, 107:269.
42. Toropova A.P., Toropov A.A., Benfenati E., Gini G., Leszczynska D., Leszczynski J. CORAL: quantitative structure-activity relationship models for estimating toxicity of organic compounds in rats. J. Comput. Chem. 2011, 32:2727.
43. Valerio L.G. In silico toxicology models and databases as FDA critical path initiative toolkits. Hum. Genomics 2011, 5:200.
44. Linkov I., Bates M.E., Trump B.D., Seager T.P., Chappell M.A., Keisler J.M. For nanotechnology decisions, use decision analysis. Nano Today 2013, 8:5.